Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Clinical Utility of Circulating Tumor Cells

December 5th 2014

Latest News & Insight: December 5, 2014

December 5th 2014

Pre-Chemo Abiraterone Extends Survival in CRPC

November 21st 2014

ADT With GnRH Antagonists in Prostate Cancer

November 21st 2014

Upcoming Advances for GU Cancers

November 21st 2014

Latest News & Insight: November 20, 2014

November 21st 2014

Recognizing the Role of Bias in Patient Decision Making

November 19th 2014

Doctors are taught to think through medical decisions by listing a series of options, weighing the risks and benefits of each, and ultimately concluding on the superior option. This comparative maximization approach is drilled into us as medical students and residents.

Dr. Sweeney on the Future of Prostate Cancer Research

November 18th 2014

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the future of prostate cancer research.

Sipuleucel-T Maker Dendreon Files for Bankruptcy

November 10th 2014

Dendreon, the maker of the first FDA-approved immunotherapy for advanced prostate cancer, sipuleucel-T (Provenge), has filed for chapter 11 bankruptcy.

Bayer Restores Access to Radium-223 for Prostate Cancer

November 6th 2014

Access to radium-223 dichloride has been restored following a temporary suspension in production by its manufacturer Bayer HealthCare Pharmaceuticals to adjust its manufacturing process to meet certain quality standards that the company has in place.

Chasing CTCs: Novel Technologies May Unlock Potential of Elusive Biomarker

October 28th 2014

Despite being discovered more than 150 years ago, tumor cells present in the blood of patients with cancer are only now inspiring significant research efforts. Technological advancements have allowed the isolation and enrichment of these rare cells and, as potential metastatic "emissaries," they have significant potential for improving the detection and treatment of advanced and possibly even early-stage disease.

Novel Drugs Are Being Studied in GU Cancers

October 25th 2014

A round-up of new drugs that are being investigated as treatments for genitourinary cancers.

Game Changers in Prostate Cancer

October 23rd 2014

Over the past 6 months, we have had two studies that will profoundly affect our management of advanced prostate cancer patients.

How Test Reimbursement Decisions Are Made: A Leader of Medicare's MolDX Program Discusses Evaluation Process

October 21st 2014

Despite the promise associated with biomarker-based tools as a means of helping to guide cancer diagnosis and treatment, there is a potential stumbling block: insurance reimbursement.

Treatment Selection in Metastatic Prostate Cancer

October 16th 2014

Convincing Long-Term Survival With Abiraterone in mCRPC

October 16th 2014

Quality of Life and Survival With Abiraterone in CRPC

October 16th 2014

Researchers Discuss Novel Therapies in NSCLC

October 16th 2014

Latest News & Insight: October 16, 2014

October 16th 2014

Radium-223 Production Halted Due to Manufacturing Glitch

October 15th 2014

Production of the prostate cancer drug radium-223 has been temporarily suspended by its maker, Bayer HealthCare Pharmaceuticals, due to a manufacturing problem.